The Architecture of Value.
Effective stock market research is not an act of prediction, but a process of elimination. Our framework provides a structured technical walkthrough for evaluating a company’s financial health with clinical detachment.
Phase I: Financial Screening
Before diving into qualitative narratives, we apply a hard filter. We ignore the industry buzz and focus exclusively on the quantitative reality found in quarterly filings and annual statements.
Gross Margin Integrity
We look for stability or expansion in gross margins over a five-year horizon. This is our primary indicator of pricing power and competitive durability.
Organic Revenue Delta
Stripping away acquisitions and currency fluctuations reveals the true internal growth rate. If the core isn't expanding, the structure is failing.
Debt-to-Earnings Ratio
Financial health requires a balance. We penalize companies with high leverage-to-operating income ratios, regardless of their current market sentiment.
OCF to Net Income Delta
We compare Operating Cash Flow (OCF) against reported Net Income. Consistent discrepancies suggest aggressive accounting practices or deteriorating working capital efficiency. Our framework requires OCF to track closely with net earnings over the business cycle.
Capital Expenditure Intensity
Is the company spending to maintain or to grow? We isolate maintenance CapEx from growth initiatives. A company that must spend 100% of its cash flow just to keep the lights on is not a vehicle for long-term compound growth.
Free Cash Flow Yield Models
Finally, we calculate the FCF yield. This is the ultimate "real" return the asset generates. We weigh this against risk-free rates and historical market averages to determine the margin of safety within the current stock price.
Phase III: Valuation Models
The Terminal Threshold.
"Valuation is not about what a stock is worth today, but what the cash flows are worth discounted by the risk of the unknown."
Discounted Cash Flow (DCF)
We avoid standard 10-year forecasts. Instead, we use a conservative 3-to-5 year window with high terminal exit hurdles. If it doesn't work with a 10% discount rate, the risk profile is too high for our framework.
PRIMARY MODELHistorical Multiple Mean-Reversion
We analyze P/E, P/S, and EV/EBITDA ratios against 10-year medians. This identifies if a high-quality company is currently mispriced by temporary market sentiment or sector-wide rotations.
SECONDARY PROOFThe Analysis Report
Our research framework culminates in a 12-page exhaustive dossier. Unlike general market summaries, our reports focus on specific failure points and base-case scenarios.
Risk Matrix Analysis
Competitor impact & regulatory hurdles
Management Stewardship Score
Capital allocation & buyback efficiency
Negative Case Stress Test
20% revenue contraction survival plan
Ready to apply the framework?
Our methodology is best understood through demonstration. Browse our latest case studies or connect with our analytical team in Melbourne.